Press release
Neurological Biomarkers Market: Pipeline Overview 2017 - 2025
The University of British Columbia and the Karolinska Institute in Sweden have set up biobanks that provide necessary resources and information for biomedical research. Alzheimer’s is the most common form of dementia affecting 12 million people. Neuroimaging and neuropsychological probes can help predict Alzheimer before behavioral tests diagnose. Thus pre-assessment tests such as Positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) are driving the demand for neurological biomarkers.
View Report Preview @ https://www.persistencemarketresearch.com/market-research/neurological-biomarkers-market.asp
The introduction of newer neurological biomarkers is expected to play a crucial role in helping neuropathologists in the characterization and selection of suitable treatment strategies. Moreover, with the advent of telehealth and personalized medicine, there is an emerging trend of single-cell biosensors as it may help integrating large-scale clinical and molecular information.
These biomarkers are used in patients suffering from acute ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage and traumatic brain injury. Recovery from such neurocritical disease depends on how well the patient mitigates. In such situations, procurement of imaging studies or a good examination may be delayed due to the complexities involved. This shortcoming has further fueled the demand for biomarkers. The market is also experiencing recent trends with the researches undertaken on novel radiotracers, miRNA, and integration of systems biology into routine biomarker validation.
The neurological market is expected to witness growth owing to the various technological developments, the expansion in application and rise in the incidence of neurological disorders such as Alzheimer's, Parkinson’s and stroke. But the industry has certain restraints such as reproduction of positive trial results, the absence of pre-analytical tests and failure to investigate the efficiency of the biomarker as compared to previous one.
Furthermore, the demand for these biomarkers is expected to propel as the demand for neurological care is increasing. In America, there are around 5.4 million people diagnosed with Alzheimer’s disease. The number is expected to triple to 16 million by 2050. The demand for procedural specialties is more as compared to on procedural specialties. This statement can be justified by the fact that the Medicare payment grew by 84% for procedural specialties and only 48% for non-procedural specialties.
On the basis of imaging techniques the neurological biomarkers market can be segment as:
Transcranial magnetic stimulation (TMS)
Diffusion tensor imaging (DTI)
Conventional structural MRI (sMRI)
Functional magnetic resonance imaging (fMRI)
Positron emission tomography (PET)
On the basis of application the neurological biomarkers market can be segment as:
Proteomics based biomarkers
Genomic based biomarkers
Imaging based biomarkers
Metabolic based biomarkers
On the basis of indication the neurological biomarkers market can be segment as:
Alzheimer's disease (AD)
Multiple sclerosis (MS)
Parkinson's disease (PD)
Autism spectrum disorder (ASD)
On the basis of end-user the neurological biomarkers market can be segment as:
Hospitals
Clinics
Diagnostic and research laboratories
On the basis of services the neurological biomarkers market can be segment as:
Sample preparation
Assay development
Biomarker validation and testing
In terms of geography, the global neurological biomarkers market has been divided into five regions including North- America, Asia- Pacific and Middle-East & Africa, Latin America and Europe. North America has a major revenue share in the neurological biomarkers industry as many prominent market players are present in this region, the number of R&D projects carried out and the government funding received by academic universities to undertake research. For instance in August 2015, researchers, patients and various non-profit organizations participated in the Imaging Dementia -- Evidence for Amyloid Scanning (IDEAS) study. The USD 100 million project aims to study the utility of amyloid PET imaging to diagnose dementia, Alzheimer’s and cognitive impairment.
Request to View TOC and Sample of Research Report @ https://www.persistencemarketresearch.com/samples/16303
Asia-Pacific is the fastest growing region as the region offers huge population base, high incidence rate of neurological abnormalities, entry of new market players and huge aging population. In developing economies such as India and China, new industry players are trying to establish their market presence by developing the generic version of the biomarker, through contract research organizations. This has further helped in reducing the manufacturing cost for the company and other production related cost.
Key players in the neurological biomarkers industry are Myriad RBM, Proteome Sciences, QIAGEN, Thermo Fisher Scientific, AbaStar MDx, Acumen Pharmaceuticals, Abiant, Aepodia, Athena Diagnostics, ImmunArray, Quanterix and Cisbio Bioassays.
About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
Telephone - +1-646-568-7751
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neurological Biomarkers Market: Pipeline Overview 2017 - 2025 here
News-ID: 969569 • Views: …
More Releases from Persistence Market Research
Sportswear Fabric Market to Reach US$40.5 Bn by 2032, Growing at 5.0% CAGR
The global sportswear fabric market is undergoing a significant transformation as consumer expectations shift toward performance, comfort, sustainability, and style. As active lifestyles and fitness-oriented habits become the global norm rather than a niche trend, the fabrics used to manufacture sportswear garments are gaining immense attention among brands, manufacturers, and material innovators.
➤ Download Your Free Sample & Explore Key Insights:
https://www.persistencemarketresearch.com/samples/30859
According to recent industry projections, the sportswear fabric market size…
Image Guided Dentals Surgery Market Set to Transform Modern Implant Dentistry
Image-guided dental surgery (IGDS) represents one of the most transformative advancements in modern dentistry. As dental practices worldwide shift toward precision-driven, minimally invasive techniques, IGDS has emerged as a critical tool for improving patient outcomes, enhancing surgical accuracy, and elevating the quality of dental care. By integrating advanced imaging systems, 3D visualization, virtual planning tools, and computer-navigation technologies, IGDS systems allow clinicians to perform complex procedures with a higher degree…
Textile Sizing Chemicals Market: Growing Demand for High-Performance and Sustain …
Introduction
Textile sizing chemicals play a crucial role in the textile manufacturing chain, particularly during the weaving process. Sizing is the step where yarns-especially warp yarns-are coated with a protective adhesive film to improve strength, reduce friction, minimize hairiness, and lower breakage during weaving. This process enhances weaving efficiency and yields higher-quality fabrics with improved texture, durability, and uniformity. Without sizing chemicals, modern high-speed looms would not be able to achieve…
2-Ethylhexanoic Acid Market Trends Transforming the Industrial Chemicals Landsca …
Introduction
2-Ethylhexanoic Acid (2-EHA) is a widely used organic carboxylic acid known for its clear-to-yellowish appearance, mild odor, and excellent solubility in organic solvents. With strong chemical stability, high boiling point, and the ability to react with metals and alcohols to form esters or metal salts, 2-EHA serves as a versatile intermediate in several industrial applications. The global market for 2-EHA is deeply influenced by trends in downstream industries such as…
More Releases for Alzheimer
Alzheimer Therapeutics Market Breakthrough Innovations and Increasing Treatment …
The Alzheimer Therapeutics Market is rapidly evolving as disease-modifying therapies, early-stage diagnostic tools, and biomarker-driven treatment approaches reshape global management of Alzheimer's disease (AD). As one of the most prevalent neurodegenerative conditions, Alzheimer's affects millions of older adults worldwide. With recent regulatory approvals of anti-amyloid monoclonal antibodies, enhanced imaging technology, and increased R&D investment, the market is experiencing unprecedented momentum.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/51928
Key Takeaways
• Disease-modifying…
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
